Patents by Inventor Thomas Ferkol

Thomas Ferkol has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhanced delivery via serpin enzyme complex receptor
    Publication number: 20060228407
    Abstract: Serpin enzyme complex receptors are used as targets for therapeutic drugs in the lungs and brain tissue. any lung or brain disease and any therapeutic drug can be targeted to the lung or brain by use of ligands which specifically bind to the receptors. Complexes for delivery may include proteins, pharmacological agents, or nucleic acids, as well as carrier molecules, and ligands for the receptors. The ligands can be coupled directly to the therapeutic agent or to a carrier molecule which binds to the therapeutic agent.
    Type: Application
    Filed: June 20, 2006
    Publication date: October 12, 2006
    Applicant: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Assem Ziady, Pamela Davis, Thomas Ferkol, Alfred Malouf
  • Fusion proteins for protein delivery
    Patent number: 6287817
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A1AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: September 11, 2001
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk
  • Fusion proteins for protein delivery
    Patent number: 6072041
    Abstract: A protein conjugate consisting of antibody directed at the pIgR and A.sub.1 AT can be transported specifically from the basolateral surface of epithelial cells to the apical surface. This approach provides us with the ability to deliver a therapeutic protein directly to the apical surface of the epithelium, by targeting the pIgR with an appropriate ligand. Thus, the highest concentration of the antiprotease will be at the apical surface, where it can do the greatest good in accelerating the inflammatory response.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: June 6, 2000
    Assignee: Case Western Reserve University
    Inventors: Pamela B. Davis, Thomas Ferkol, Elizabeth Eckman, John Schreiber, John M. Luk